CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals (AMEX: IDP) today announced the publication of preclinical data demonstrating that its Toll-like Receptor (TLR) 9 agonist in combination with bevacizumab, the anti-vascular endothelial growth factor (VEGF) monoclonal antibody, resulted in co-operative anti-tumor activity in animal models of colon cancer. Bevacizumab is marketed as Avastin®. The paper entitled “Novel TLR9 agonist synergizes by different mechanisms with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts” is published in the Proceedings of National Academy of Sciences (Vol. 104: 12468-12473, 2007). The authors of the paper include Vincenzo Damiano, Rosa Caputo, Sonia Garofalo, Roberto Bianco, Roberta Rosa, Luigi Racioppi, Gerardina Merola, Sabino De Placido, Fortunato Ciardiello, Gabriella Fontanini and Giampaolo Tortora of the University of Naples Federico II and University of Pisa, Italy; and Ekambar Kandimalla and Sudhir Agrawal of Idera.
